Development of an improved live attenuated antigenic marker CSF vaccine strain candidate with an increased genetic stability

被引:19
|
作者
Holinka, L. G. [1 ,2 ]
Fernandez-Sainz, I. [1 ]
Sanford, B. [1 ]
O'Donnell, V. [1 ,2 ]
Gladue, D. P. [1 ,2 ]
Carlson, J. [1 ]
Lu, Z. [3 ]
Risatti, G. R. [2 ]
Borca, M. V. [1 ]
机构
[1] ARS, Plum Isl Anim Dis Ctr, USDA, Greenport, NY 11944 USA
[2] Univ Connecticut, Dept Pathobiol & Vet Sci, Storrs, CT 06269 USA
[3] DHS, Plum Isl Anim Dis Ctr, Greenport, NY 11944 USA
关键词
Marker vaccine; DIVA strategy; Protection; Minimal protective dose; Vaccine safety; Classical swine fever virus; CLASSICAL SWINE-FEVER; HOG-CHOLERA VIRUS; VIRULENCE DETERMINANT; E-RNS; E2; GLYCOPROTEIN; PESTIVIRUS; ANTIBODIES; NS4B;
D O I
10.1016/j.virol.2014.09.021
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Controlling classical swine fever (CSF) involves vaccination in endemic regions and preemptive slaughter of infected swine herds during epidemics. Live attenuated marker vaccines that confer effective protection against the disease and allow differentiation between infected and vaccinated animals (DIVA) could impact CSF control policies. Previously, we reported the development of FlagT4 virus (FlagT4v), a rationally designed live attenuated marker vaccine. During its vaccine assessment, FlagT4v reverted to a virulent virus during successive passages in piglets. Sequence analysis revealed deletions and substitutions almost exclusively in the areas of El and E2. To improve genetic stability of FlagT4v, we introduced changes in the codon usage in those areas. The newly developed virus, FlagT4Gv, was shown to retain the attenuated phenotype after successive passages in piglets. As observed with FlagT4v, the newly developed FlagT4Gv conferred effective protection against challenge with virulent CSFV at early (7 days) and at late (28 days) times post-vaccination. Published by Elsevier Inc.
引用
收藏
页码:13 / 18
页数:6
相关论文
共 50 条
  • [31] Genetic stability determinants of temperature sensitive, live attenuated respiratory syncytial virus vaccine candidates
    Lin, YH
    Deatly, AM
    Chen, W
    Miller, LZ
    Lerch, R
    Sidhu, MS
    Udem, SA
    Randolph, VB
    VIRUS RESEARCH, 2006, 115 (01) : 9 - 15
  • [32] Development of a live attenuated vaccine candidate for equid alphaherpesvirus 1 control: a step towards efficient protection
    Hu, Yue
    Wu, Guiling
    Jia, Qinrui
    Zhang, Baozhong
    Sun, Wencheng
    Sa, Ruixue
    Zhang, Siyu
    Cai, Weifan
    Ran, Duoliang
    Liu, Jianhua
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [33] Generation of a Live-Attenuated Strain of Chikungunya Virus from an Indian Isolate for Vaccine Development
    Nair, Sreeja R. R.
    Abraham, Rachy
    Sreekumar, Easwaran
    VACCINES, 2022, 10 (11)
  • [34] Efficacy of Gpe− Strain Live Attenuated Vaccine and Cp7_E2alf Strain Recombinant Live Vaccine (Marker Vaccine) Against Japanese Epidemic Classical Swine Fever Virus Isolated in 2019 and Diva Discrimination Ability of the Marker Vaccine
    Yamashitaa, Maiko
    Iwamoto, Shoko
    Ochiai, Mariko
    Sudo, Kasumi
    Nagasaka, Takao
    Saito, Akito
    Kozasa, Takashi
    Omatsu, Tsutomu
    Mizutani, Tetsuya
    Yamamoto, Kinya
    SSRN,
  • [35] An attenuated West Nile prototype virus is highly immunogenic and protects against the deadly NY99 strain: a candidate for live WN vaccine development
    Yamshchikov, G
    Borisevich, V
    Seregin, A
    Chaporgina, E
    Mishina, M
    Mishin, V
    Kwok, CW
    Yamshchikov, V
    VIROLOGY, 2004, 330 (01) : 304 - 312
  • [36] Disruption of the cpsE and endA Genes Attenuates Streptococcus pneumoniae Virulence: Towards the Development of a Live Attenuated Vaccine Candidate
    Amonov, Malik
    Simbak, Nordin
    Wan Hassan, Wan Mohd. Razin
    Ismail, Salwani
    A. Rahman, Nor Iza
    Clarke, Stuart C.
    Yeo, Chew Chieng
    VACCINES, 2020, 8 (02)
  • [37] Development of a fast-dissolving tablet formulation of a live attenuated enterotoxigenic E. coli vaccine candidate
    Lal, Manjari
    Priddy, Scott
    Bourgeois, Lou
    Walker, Richard
    Pebley, Walt
    Brown, James
    Desai, James
    Darsley, Michael J.
    Kristensen, Debra
    Chen, Dexiang
    VACCINE, 2013, 31 (42) : 4759 - 4764
  • [38] Development of an auxotrophic, live-attenuated Brucella suis vaccine strain capable of expressing multimeric GnRH
    Smith, G. P.
    Jain-Gupta, N.
    Alqublan, H.
    Dorneles, E. M. S.
    Boyle, S. M.
    Sriranganathan, N.
    VACCINE, 2019, 37 (07) : 910 - 914
  • [39] Development of a live attenuated duck hepatitis A virus type 3 vaccine (strain SD70)
    Wu, Fengyao
    Lu, Fengying
    Fan, Xin
    Pan, Qunxing
    Zhao, Sha
    Sun, Huawei
    Zhang, Jingfeng
    Liu, Chuanmin
    Chao, Jin
    Zhang, Xiaofei
    VACCINE, 2020, 38 (30) : 4695 - 4703
  • [40] Further molecular characterization and stability of the live oral attenuated cholera vaccine strain CVD103-HgR
    Favre, D
    Struck, MM
    Cryz, SJ
    Viret, JF
    VACCINE, 1996, 14 (06) : 526 - 531